Usefulness of salivary and serum auto-antibodies against tumor biomarkers HER2 and MUC1 in breast cancer screening

Asian Pacific Journal of Cancer Prevention

Volumn 17, Issue 1, 2016, Pages 335-339

  Laidi, Fatna ^a   Bouziane, Amal ^a   Errachid, Abdelhamid ^b   Zaoui, Fatima ^a  

^a MOHAMMED V UNIVERSITY IN RABAT   (Morocco)

^b UNIVERSITÉ DE LYON   (France)

Author keywords

Autoantibodies; Breast cancer; HER2; MUC1; Saliva; Serum

Indexed keywords

AUTOANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MUC1 PROTEIN, HUMAN; MUCIN 1; TUMOR MARKER;

BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; SALIVA; SERUM;

AUTOANTIBODIES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MIDDLE AGED; MUCIN-1; RECEPTOR, ERBB-2; SALIVA; SERUM;

EID: 84957966266     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2016.17.1.335     Document Type: Article

References (33)

1. Al Kawas S, Rahim ZH, Ferguson DB (2012). Potential uses of human salivary protein and peptide analysis in the diagnosis of disease. Arch Oral Biol, 57, 1-9.
2. Arif S, Qudsia S, Urooj S, et al (2014). Blueprint of quartz crystal microbalance biosensor for early detection of breast cancer through salivaryautoantibodies against ATP6AP1. Biosens Bioelectron, 65, 62-70.
3. Atoum M, Nimer N, Abdeldayem S, et al (2012). Relationships among serum CA15-3 tumor marker, tnm staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions. Asian Pac J Cancer Prev, 13, 857-60.
4. Begum M, Karim S, Malik A, et al (2012). CA 15-3 (mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev, 13, 5257-1.
5. Chapman C, Murray A, Chakrabarti J, et al (2007). Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol, 18, 868-3.
6. Chapman CJ, Murray A, McElveen JE, et al (2008). Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax, 63, 228-33.
7. Desmetz C, Lacombe J, Mange A, et al (2011). Autoanticorps et diagnostic précoce des cancers. Med Sci, 27, 633-8.
8. Evans RL, Pottala JV, Egland KA (2014). Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. Cancer Prev Res, 7, 545-5.
9. Gendler S, Taylor-Papadimitriou J, Duhig T, et al (1988). A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem, 263, 12820-3.
10. Humphrey SP, Williamson RT (2001). A review of saliva: normal composition, flow, and function. J Prosthet Dent, 85, 162-9.
11. Isla Larrain MT, Colussi AG, Demichelis SO, et al (2013). Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients. Int J Biol Markers, 28, 318-5.
12. Kufe DW (2013). MUC1-C Oncoprotein as a Target in Breast Cancer; Activation of Signaling Pathways and Therapeutic Approaches. Oncogene, 32, 1073-1.
13. Laidi F, Bouziane A, Lakhdar A, et al (2014). Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status. Onco Targets Ther, 7, 1285-9.
14. Laidi F, Bouziane A, Lakhdar A, et al (2014). Significant correlation between salivary and serum Ca 15-3 in healthy women and breast cancer patients. Asian Pac J Cancer Prev, 15, 4659-2.
15. Lamster IB, Ahlo JK (2007). Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci, 1098, 216-9.
16. Lu H, Ladd J, Feng Z, et al (2012). Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res, 5, 1036-3.
17. Maric P, Ozretic P, Levanat S, et al (2011). Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol, 35, 241-7.
18. Moazzezy N, Farahany T-Z, Oloomi M, et al (2014). Relationship between preoperative serum CA15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pac J Cancer Prev, 15, 1685-8.
19. Murphy MA, O'Leary JJ, Cahill DJ (2012). Assessment of the humoral immune response to cancer. J Proteomics, 75, 4573-9.
20. Muss HB, Thor AD, Berry DA, et al (1994). c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med, 330, 1260-6.
21. Pinkhasov J, Alvarez ML, Rigano MM, et al (2011). Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice. Plant Biotechnol J, 9, 991-1.
22. Porika M, Malotu N, Veldandi U-K, et al (2010). Evaluation of tumor markers in Southern Indian breast cancer patients. Asian Pac J Cancer Prev, 11, 157-9.
23. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science, 235, 177-2.
24. Sotelo MJ, García-Sáenz JA, Manso L, et al (2014). Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. J Cancer Res Ther, 10, 967-2.
25. Tang Y, Wang L, Zhang P, et al (2010). Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol, 17, 1903-8.
26. Tarhan M-O, Gonel A, Kucukzeybek Y, et al (2013). Prognostic significance of circulating tumor cells and serum ca15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac J Cancer Prev, 14, 1725-9.
27. Tarhan Geeraert N, Klausz R, Cockmartin L, et al (2014). Comparison of volumetric breast density estimations from mammography and thorax CT. Phys Med Biol, 59, 4391-9.
28. Tjemslanda L and Soreide JA (2004). Operable breast cancer patients with diagnostic delay oncological and emotional characteristics. Eur J Surg Oncol, 30, 721-7.
29. Treon SP, Maimonis P, Bua D, et al (2000). Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood, 96, 3147-3.
30. Tsé C (2010). sHER-2: a novel marker? Med Nucl, 34, 66-1.
31. Wang YQ, Zhang HH, Liu CL, et al (2012). Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer. Asian Pac J Cancer Prev, 13, 5557-2.
32. Warnakulasuriya S, Soussi T, Maher R, et al (2000). Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients. J Pathol, 192, 52-7.
33. Zhang S-J, Hu Y, Qian H-L, et al (2013). Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev, 14, 3937-40.